Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Concurrent chronic hyperplastic candidosis and oral lichenoid lesion as adverse events of secukinumab therapy

Published:2021-03-05 Issue:3 Volume:66 Page:340-345
ISSN:0045-0421
Container-title:Australian Dental Journal
language:en
Short-container-title:Aust Dent J

Author:

Farah CS¹²³^ORCID

Affiliation:

1. The Oral Medicine Clinic Hollywood Private Hospital Nedlands Western Australia Australia

2. Anatomical Pathology Australian Clinical Labs Subiaco Western Australia Australia

3. Australian Centre for Oral Oncology Research & Education Perth Western Australia Australia

Publisher

Wiley

Subject

General Dentistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/adj.12833

Reference41 articles.

1. Novartis.Cosentyx.2020;https://www.cosentyx.com/. Accessed 3 April 2020.

2. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

3. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

4. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

5. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting Chronic Hyperplastic Candidiasis Retro-Angular Mucosa Using Machine Learning;Clinics and Practice;2023-10-28

2. Detection of IL-17A and IL-17F gene polymorphism in recurrent and disseminated pityriasis versicolor: a case-control study;Archives of Dermatological Research;2022-11-30

3. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab;Pharmaceuticals;2022-11-07

4. The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition;Journal of Dermatological Treatment;2022-04-08

5. Oral Candida Infection in Psoriatic Patients Treated with IL17A Inhibitors: Report of 3 Cases and a Comprehensive Review of the Literature;Diagnostics;2021-12-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3